Layer3.news

AI by layer3.news

Filtering by: Rob Michael · clear filter

THE TOP 5 ANALYST QUESTIONS FROM ABBVIE’S Q3 EARNINGS CALL

https://s.yimg.com/ny/api/res/1.2/kHOxyMj_cOakofKhZcoUPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8

✍️ AbbVie's third quarter results showed strong revenue growth, driven by immunology and neuroscience portfolios, but the market reacted negatively due to a sharp drop in operating margin and headwinds in the aesthetics segment.

👉 Revenue growth driven by immunology and neuroscience portfolios 👉 Sales growth from Skyrizi and Rinvoq 👉 Double-digit expansion in neuroscience products 👉 Sharp drop in operating margin 👉 Headwinds in the aesthetics segment

-- #RobMichael #TerenceFlynn #ChristopherSchott #VamilDivan #DavidAmsellem #GeoffreyMeacham #RoopalThakkar #JeffreyStewart #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqc7gtg2gyjq9umj4lwj0n2lkdz2e6nlsvsdtfcy5ycz2yv7cxzv0s07pa9f

Rob Michael Terence Flynn Christopher Schott Vamil Divan David Amsellem Geoffrey Meacham Roopal Thakkar Jeffrey Stewart

11/8/2025

npub1vap2usg…grwc3n

WHERE WILL ABBVIE BE IN 5 YEARS?

https://s.yimg.com/ny/api/res/1.2/cI6lgPaAEiL5X5YhO_kjfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/62567cee84a2a0c2db4f4d900123880b

✍️ AbbVie, a pharmaceutical company, is expected to deliver double-digit annual total returns through the end of the decade, but its future is uncertain due to various factors.

👉 AbbVie is expected to be less dependent on Humira in five years 👉 Skyrizi and Rinvoq are expected to become bigger winners 👉 Other drugs in AbbVie's lineup are expected to continue their winning ways 👉 Tariffs on pharmaceutical imports could impact AbbVie's profits 👉 The broader economy could impact AbbVie's share price 👉 The success of AbbVie's pipeline programs is uncertain

-- #RobMichael #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqlyxkafn79g46v06xxyz0ekhlp69un0rv2vuh5dn4w0whqhhjpdrsz7vzvl

Rob Michael business mainstream:perspective

9/26/2025

npub1vap2usg…grwc3n

PHARMA CEOS DOWNPLAY IMPACT OF TARIFFS AMID RISING COST CONCERNS

https://s.yimg.com/ny/api/res/1.2/98U9pDfJdODzS7.fqwOr8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03MjA-/https://media.zenfs.com/en/pharmaceutical_technology_376/2dae1805a013db1acdd3327ab9efc296

✍️ Pharma CEOs in the US and Europe remain confident that the latest US-EU trade deal will have a limited impact on their companies, despite analyst warnings of heightened financial risk.

👉 US-EU trade deal introduces 15% tariff on pharmaceuticals 👉 Analysts predict increased costs and reduced pricing leverage for pharma companies 👉 Pharma CEOs downplay impact, citing ability to manage risks and maintain profitability 👉 Tariffs could lead to higher drug prices for patients 👉 Pharma companies are already under pressure due to R&D budgets and tariffs

-- #DiederikStadig #RobMichael #PascalSoriot #RobDavis #US #Europe #Virginia #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqdffhadyg0gdyq44pl6h45hzp79kewe7pzupj3wg4gs34vqs7khdqw3gg2f

Diederik Stadig Rob Michael Pascal Soriot Rob Davis US Europe Virginia business

8/4/2025

npub1vap2usg…grwc3n

3 DIVIDEND CHAMPION STOCKS I'M WATCHING IN 2025

https://s.yimg.com/ny/api/res/1.2/Bg3.NVeJjodrwl0wS4f2UA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/915cbb9e029eed8d68e7e4a15c6dd3db

✍️ The article discusses three Dividend Champion stocks, AbbVie, Chevron, and Target, that investors may consider for their dividend yield and potential growth.

👉 AbbVie is a Dividend King with a 53-year streak of dividend increases 👉 Chevron is a Dividend Champion with 38 consecutive years of dividend increases 👉 Target is a Dividend King with a 54-year streak of dividend increases 👉 AbbVie's stock may be a good buying opportunity if pharmaceutical tariffs cause a decline in its share price 👉 Chevron's acquisition of Hess may lead to a delayed impact on its stock price 👉 Target faces multiple challenges, including a customer backlash and declining consumer confidence

-- #RobMichael #SteveScala #DonaldTrump #KeithSpeights #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqzrmdka37tlrrzrcf843t4uh7mmk9w8he9gzhr2x5rmff48lgsg3qr7rsr9

Rob Michael Steve Scala Donald Trump Keith Speights business mainstream:perspective

8/3/2025

npub1vap2usg…grwc3n

U.S. PHARMACEUTICAL IMPORTS MIGHT SOON FACE TARIFFS: 3 STOCKS THAT COULD TUMBLE AS A RESULT

https://s.yimg.com/ny/api/res/1.2/ge427lqq05VnIZ7.PzacZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/465f1874049f0803819279b5d3ae0ec7

✍️ The article discusses the potential impact of tariffs on the pharmaceutical industry, specifically on three companies: Amgen, Pfizer, and AbbVie. The companies' reliance on foreign-made drugs and components could lead to increased costs and reduced profit margins.

👉 Amgen's generic drug business could be hit particularly hard by tariffs 👉 Pfizer's international tax-saving strategies are under attack 👉 AbbVie's apparent disregard for tariffs doesn't align with its plans to expand domestic production 👉 Tariffs could lead to increased costs and reduced profit margins for pharmaceutical companies 👉 Companies may need to build new facilities or shift production to the US to avoid tariffs

-- #DonaldTrump #AlbertBourla #RobMichael #Ireland #Singapore #Germany #Netherlands #PuertoRico #China #UnitedStates #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqz94syz0c2pgpv702xd835c63kx54j09k5dekgwfmnc0l4af2y3mql6k0zs

Donald Trump Albert Bourla Rob Michael Ireland Singapore Germany Netherlands Puerto Rico

5/25/2025

npub12gl86km…jhagp2

MY FAVORITE DIVIDEND KING TO BUY IN NOVEMBER

https://media.zenfs.com/en/motleyfool.com/8757f47d623b74fee5bf5beafb8a06df

✍️ The article discusses the importance of dividend stocks and highlights AbbVie as a top pick among Dividend Kings, a group of companies that have increased their dividend payouts for at least 50 consecutive years.

👉 AbbVie is a Dividend King with a 52-year streak of annual dividend increases 👉 The company has increased its dividend payout by 310% since its spinoff from Abbott Laboratories 👉 AbbVie's forward dividend yield is 3.26%, nearly 2.7 times higher than the S&P 500 👉 The company has a strong track record of navigating challenges, including the decline of its top-selling drug Humira 👉 AbbVie has a pipeline of over 90 programs and has completed 15 deals this year

-- #RobMichael #ScottReents #KeithSpeights #mainstream #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzq53704dkn2v2nsehgyzexn9y92sny3j7t7yewycj0lauss6n99zuqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqmy05e6n2rqcr8t8jnlrzwvzaf3wndzrjtvptyg0uu275fyfctm5qx76h34

Rob Michael Scott Reents Keith Speights mainstream business mainstream:perspective

11/9/2024

Layer3.news

AI by layer3.news

Filtering by: Rob Michael · clear filter

npub1vap2usg…grwc3n

THE TOP 5 ANALYST QUESTIONS FROM ABBVIE’S Q3 EARNINGS CALL

https://s.yimg.com/ny/api/res/1.2/kHOxyMj_cOakofKhZcoUPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8

✍️ AbbVie's third quarter results showed strong revenue growth, driven by immunology and neuroscience portfolios, but the market reacted negatively due to a sharp drop in operating margin and headwinds in the aesthetics segment.

-- #RobMichael #TerenceFlynn #ChristopherSchott #VamilDivan #DavidAmsellem #GeoffreyMeacham #RoopalThakkar #JeffreyStewart #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqc7gtg2gyjq9umj4lwj0n2lkdz2e6nlsvsdtfcy5ycz2yv7cxzv0s07pa9f

Rob Michael Terence Flynn Christopher Schott Vamil Divan David Amsellem Geoffrey Meacham Roopal Thakkar Jeffrey Stewart

11/8/2025

npub1vap2usg…grwc3n

WHERE WILL ABBVIE BE IN 5 YEARS?

https://s.yimg.com/ny/api/res/1.2/cI6lgPaAEiL5X5YhO_kjfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/62567cee84a2a0c2db4f4d900123880b

✍️ AbbVie, a pharmaceutical company, is expected to deliver double-digit annual total returns through the end of the decade, but its future is uncertain due to various factors.

-- #RobMichael #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqlyxkafn79g46v06xxyz0ekhlp69un0rv2vuh5dn4w0whqhhjpdrsz7vzvl

Rob Michael business mainstream:perspective

9/26/2025

npub1vap2usg…grwc3n

PHARMA CEOS DOWNPLAY IMPACT OF TARIFFS AMID RISING COST CONCERNS

https://s.yimg.com/ny/api/res/1.2/98U9pDfJdODzS7.fqwOr8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03MjA-/https://media.zenfs.com/en/pharmaceutical_technology_376/2dae1805a013db1acdd3327ab9efc296

✍️ Pharma CEOs in the US and Europe remain confident that the latest US-EU trade deal will have a limited impact on their companies, despite analyst warnings of heightened financial risk.

-- #DiederikStadig #RobMichael #PascalSoriot #RobDavis #US #Europe #Virginia #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqdffhadyg0gdyq44pl6h45hzp79kewe7pzupj3wg4gs34vqs7khdqw3gg2f

Diederik Stadig Rob Michael Pascal Soriot Rob Davis US Europe Virginia business

8/4/2025

npub1vap2usg…grwc3n

3 DIVIDEND CHAMPION STOCKS I'M WATCHING IN 2025

https://s.yimg.com/ny/api/res/1.2/Bg3.NVeJjodrwl0wS4f2UA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/915cbb9e029eed8d68e7e4a15c6dd3db

✍️ The article discusses three Dividend Champion stocks, AbbVie, Chevron, and Target, that investors may consider for their dividend yield and potential growth.

-- #RobMichael #SteveScala #DonaldTrump #KeithSpeights #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqzrmdka37tlrrzrcf843t4uh7mmk9w8he9gzhr2x5rmff48lgsg3qr7rsr9

Rob Michael Steve Scala Donald Trump Keith Speights business mainstream:perspective

8/3/2025

npub1vap2usg…grwc3n

U.S. PHARMACEUTICAL IMPORTS MIGHT SOON FACE TARIFFS: 3 STOCKS THAT COULD TUMBLE AS A RESULT

https://s.yimg.com/ny/api/res/1.2/ge427lqq05VnIZ7.PzacZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/465f1874049f0803819279b5d3ae0ec7

✍️ The article discusses the potential impact of tariffs on the pharmaceutical industry, specifically on three companies: Amgen, Pfizer, and AbbVie. The companies' reliance on foreign-made drugs and components could lead to increased costs and reduced profit margins.

-- #DonaldTrump #AlbertBourla #RobMichael #Ireland #Singapore #Germany #Netherlands #PuertoRico #China #UnitedStates #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqz94syz0c2pgpv702xd835c63kx54j09k5dekgwfmnc0l4af2y3mql6k0zs

Donald Trump Albert Bourla Rob Michael Ireland Singapore Germany Netherlands Puerto Rico

5/25/2025

npub12gl86km…jhagp2

MY FAVORITE DIVIDEND KING TO BUY IN NOVEMBER

https://media.zenfs.com/en/motleyfool.com/8757f47d623b74fee5bf5beafb8a06df

✍️ The article discusses the importance of dividend stocks and highlights AbbVie as a top pick among Dividend Kings, a group of companies that have increased their dividend payouts for at least 50 consecutive years.

-- #RobMichael #ScottReents #KeithSpeights #mainstream #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzq53704dkn2v2nsehgyzexn9y92sny3j7t7yewycj0lauss6n99zuqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqmy05e6n2rqcr8t8jnlrzwvzaf3wndzrjtvptyg0uu275fyfctm5qx76h34

Rob Michael Scott Reents Keith Speights mainstream business mainstream:perspective

11/9/2024